Sinopharm Group Balance Sheet Health
Financial Health criteria checks 6/6
Sinopharm Group has a total shareholder equity of CN¥17.9B and total debt of CN¥239.7M, which brings its debt-to-equity ratio to 1.3%. Its total assets and total liabilities are CN¥33.6B and CN¥15.6B respectively. Sinopharm Group's EBIT is CN¥22.3B making its interest coverage ratio 10.7. It has cash and short-term investments of CN¥8.6B.
Key information
1.3%
Debt to equity ratio
CN¥239.71m
Debt
Interest coverage ratio | 10.7x |
Cash | CN¥8.62b |
Equity | CN¥17.94b |
Total liabilities | CN¥15.61b |
Total assets | CN¥33.55b |
Recent financial health updates
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Aug 23Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22Is Sinopharm Group (HKG:1099) A Risky Investment?
Jan 15Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Sep 05Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Jun 01These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Feb 27Recent updates
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Aug 23The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet
Jul 27Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956
Jun 16Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?
May 13Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital
Mar 21Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?
Mar 06Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?
Jan 31Is Sinopharm Group (HKG:1099) A Risky Investment?
Jan 15There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding
Dec 31Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)
Nov 29If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity
Nov 14Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?
Nov 01Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?
Sep 20Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Sep 05Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Aug 18Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?
Aug 02Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Jun 01Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
Apr 26These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Feb 27Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger
Jan 19Is Sinopharm Group (HKG:1099) A Risky Investment?
Nov 18Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down
Oct 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jul 31Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Jul 10Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement
Jun 05We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt
Apr 11A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Mar 21Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns
Mar 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jan 09Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price
Dec 19Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Dec 01These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Sep 23A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)
Sep 10Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing
Aug 28Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84
Jun 13Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Jun 06Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value
May 24Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
May 11Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?
Mar 20We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt
Mar 05You Have To Love Sinopharm Group Co., Ltd.'s (HKG:1099) Dividend
Feb 18Should You Be Impressed By Sinopharm Group's (HKG:1099) Returns on Capital?
Feb 03Should You Use Sinopharm Group's (HKG:1099) Statutory Earnings To Analyse It?
Jan 19Financial Position Analysis
Short Term Liabilities: 1099's short term assets (CN¥29.2B) exceed its short term liabilities (CN¥14.4B).
Long Term Liabilities: 1099's short term assets (CN¥29.2B) exceed its long term liabilities (CN¥1.3B).
Debt to Equity History and Analysis
Debt Level: 1099 has more cash than its total debt.
Reducing Debt: 1099's debt to equity ratio has reduced from 97.2% to 1.3% over the past 5 years.
Debt Coverage: 1099's debt is well covered by operating cash flow (6788.6%).
Interest Coverage: 1099's interest payments on its debt are well covered by EBIT (10.7x coverage).